KLI
Login
OAK 국가리포지터리
검색
커뮤니티
제목
저자
키워드
발행일
Ulsan Univ. Repository
Browsing by 키워드 : Immune checkpoint inhibitor
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
가
나
다
라
마
바
사
아
자
차
카
타
파
하
All
가
나
다
라
마
바
사
아
자
차
카
타
파
하
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
또는 첫 단어:
정렬 기준:
제목
발행일
제출일
정렬:
오름차순
내림차순
결과 수
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
저자 수
All
1
3
5
10
15
20
25
30
35
40
45
50
전체 결과 10건 중 1-10 번을 표시중입니다.
1
Article
Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma
2023
2
Article
Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease
김상위
;
김수한
;
김우성
;
et al
2020
3
Article
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors
이재련
;
Alexandra Drakaki
;
Archana Agarwal
;
et al
2021
4
Article
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
김나영
;
최우선
;
이동희
;
et al
2021
5
Article
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
김나영
;
최우선
;
이동희
;
et al
2021
6
Article
Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis
김평화
;
서종현
;
김호성
;
et al
2021
7
Article
Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis
2023
8
Article
Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab
Hyung-Don Kim
;
Min-Hee Ryu
;
Young Soo Park
;
et al
2022
9
Article
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Jeffrey Graham
;
John Connor Wells
;
Shaan Dudani
;
et al
2022
10
Article
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru P Sonpavde
;
Cora N Sternberg
;
Yohann Loriot
;
et al
2022
1
Anonymous
Login
커뮤니티
제목
저자
키워드
발행일
Guide